Jazz Pharmaceuticals JAZZ Xywav — Revenue from Contract with Customer, Excluding Assessed Tax
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's xywav — revenue from contract with customer, excluding assessed tax.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's xywav — revenue from contract with customer, excluding assessed tax?
- Jazz Pharmaceuticals (JAZZ) reported xywav — revenue from contract with customer, excluding assessed tax of $408.2M in Q1 2026.
- How has Jazz Pharmaceuticals's xywav — revenue from contract with customer, excluding assessed tax changed year-over-year?
- Jazz Pharmaceuticals's xywav — revenue from contract with customer, excluding assessed tax increased by 18.4% year-over-year, from $344.8M to $408.2M.
- What is the long-term trend for Jazz Pharmaceuticals's xywav — revenue from contract with customer, excluding assessed tax?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's xywav — revenue from contract with customer, excluding assessed tax has grown at a 32.6% compound annual growth rate (CAGR), from $535.3M to $1.66B.
- What does xywav — revenue from contract with customer, excluding assessed tax mean?
- The total net revenue earned from sales of a specific product after adjusting for all commercial deductions.
- How do you interpret xywav — revenue from contract with customer, excluding assessed tax?
- An increase reflects strong market demand, successful commercial execution, or effective pricing strategies, while a decrease may signal market saturation or competitive pressure.
- How does xywav — revenue from contract with customer, excluding assessed tax compare across companies?
- This is a standard segment revenue reporting metric used by all biopharmaceutical companies to disclose performance of key commercialized drugs.